HIV Treatment
Dolutegravir + Rilpivirine HIV Maintenance Regimen Looks Good in Phase 3 Studies
- Details
- Category: HIV Treatment
- Published on Tuesday, 27 December 2016 00:00
- Written by Liz Highleyman
Switching to a 2-drug regimen of dolutegravir plus rilpivirine maintained viral suppression among people on successful 3- or 4-drug antiretroviral therapy (ART) in a pair of Phase 3 clinical trials, according to an announcement last week from ViiV Healthcare.
2. Quicker, Simpler, and Better Antiretroviral Therapy
- Details
- Category: HIV Treatment
- Published on Thursday, 22 December 2016 00:00
- Written by HIVandHepatitis.com
Modern antiretroviral therapy (ART) is highly effective and well-tolerated, but researchers continue to refine, streamline, and optimize treatment strategies. Studies presented this year show the benefits of starting ART as soon as possible after HIV diagnosis and suggest that fewer drugs taken less often may be effective for many people.
UCSF/amfAR HIV Cure Summit Reviews Progress in Cure-Related Research
- Details
- Category: Search for a Cure
- Published on Wednesday, 21 December 2016 00:00
- Written by Liz Highleyman
Researchers at the amfAR Institute for HIV Cure Research at the University of California at San Francisco (UCSF) presented an update on their latest cure-related work at a World AIDS Day summit on December 1. This multidisciplinary effort aims to understand HIV reservoirs within the body and ultimately to control or eliminate the virus.
3. Renewed Focus on HIV Vaccines and Antibodies
- Details
- Category: Search for a Cure
- Published on Thursday, 22 December 2016 00:00
- Written by HIVandHepatitis.com
Researchers intensified the search for novel types of therapies to prevent, treat, and potentially cure HIV, including immune-based strategies such as antibodies and vaccines.
Advocates Call for More Research on Immune-Enhancing Therapies for People with HIV
- Details
- Category: HIV Treatment
- Published on Thursday, 15 December 2016 00:00
- Written by HIVandHepatitis.com
HIV/AIDS activists recently issued a call for expanded research to accelerate the development of immune-enhancing therapies for HIV-positive immunological non-responders -- people who achieve viral suppression on antiretroviral therapy but do not see their CD4 T-cell count return to near-normal levels, and therefore remain at increased risk of illness and death.
More Articles...
- World AIDS Day: 18 Million Now on HIV Treatment but Many Still Lack Access
- HIV Glasgow: 4-Days-On-3-Days-Off HIV Treatment Controls Viral Load in Pilot Study
- HIV Glasgow: Long-Acting HIV Fusion Inhibitor Albuvirtide Regimen Matches Standard Therapy
- HIV Glasgow: Darunavir/Ritonavir + Lamivudine Matches Triple-Drug HIV Therapy
Web Design and Development by